NOXXON Expands Management Team

Berlin, (PresseBox) - Noxxon Pharma AG (website), announced today the appointment of Dr.Matthias Baumann as Chief Medical Officer and member of the management board of the company.

Dr Baumann joins NOXXON from FOCUS Clinical Drug Development, Neuss/Düsseldorf, Germany where he spent 8 years in the position of Chief Scientific Officer and Managing Director. Prior to his role with Focus, Dr. Baumann held a number of positions in pre-clinical and clinical development with Hoffmann La Roche and Boehringer Mannheim.

Commenting on his appointment Mr. Iain Buchanan, Chief Executive Officer of NOXXON, said, "I am pleased to welcome Matthias to the management team at Noxxon. He brings valuable development experience to the company at a time when we will look to advance multiple pipeline projects through clinical proof of concept in the coming 24 months"

"I'm excited to contribute to the translation of the ground-breaking Spiegelmer technology into clinically meaningful therapeutics" said Dr. Matthias Baumann.

About Spiegelmers®

Spiegelmers® (L-stereoisomer RNA oligonucleotides) are chemical entities based on synthetic mirror-image oligonucleotides which are highly selective for their pharmacological target and potent inhibitors of target function. They combine the benefits of small molecule drugs and biopharmaceuticals. Due to their unique mirror-image configuration Spiegelmers are not metabolized and do not hybridize with native nucleic acids. Spiegelmers also do not activate the innate immune response via toll-like receptors and showed an exceptionally favorable immunogenicity profile in pre-clinical testing.

Noxxon Pharma AG

NOXXON Pharma AG is a biotechnology company developing a promising new class of therapeutics called Spiegelmers®, which are oligonucleotides made from the L-stereoisomer of RNA. Spiegelmers® can be engineered to bind specifically to a precisely defined biological target and have been shown to be potent inhibitors. Clinical and pre-clinical studies of Spiegelmers® to date have shown them to be exceptionally safe, well-tolerated, biologically stable and non-immunogenic. NOXXON has three programs in development, two of which, NOX-E36 and NOX-A12 have successfully completed their first Phase I clinical studies. The company has approximately 70 employees based at its headquarters in Berlin.

NOXXON's investors are NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, The Dow Chemical Company, Dieckell Group, Oppenheim Asset Management Services, IBG Risikokapitalfonds, VC Fonds Berlin, CD Ventures and others.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.